Company Overview and News

 
Claris Lifesciences to delist from March 22

2018-03-12 thehindubusinessline
Our Bureau Shares of Claris Lifesciences will be delisted from the BSE from March 22, the pharma firm announced on Monday and added that trading in the shares will be stopped from March 15.

 
Carlyle, Advent to submit bids for stake in Mankind Pharma

2018-03-05 livemint
Mumbai: Private equity funds Carlyle Group and Advent International are poised to submit binding offers to buy a minority stake in Mankind Pharma Ltd, according to two people familiar with the matter.

 
Claris Lifesciences: Delisting offer begins

2018-02-09 thehindubusinessline
The delisting offer to the shareholders of Claris Lifesciences will open on Monday at the BSE. The company, which fixed the floor price at ₹351.60, plans to buy 2.72 crore shares from the public. The open offer closes on February 20. Shares of the company are not listed on the NSE. Non-promoters, including East Bridge Capital, Goldman Sachs, Cobra India and Morgan Stanley, currently hold 49.87 per cent stake in Claris Lifesciences.

 
What to Watch: Eyes on PNB, Lupin, Hero Moto results

2018-02-05 thehindubusinessline
Among these are ABG Shipyard, Advanced Enzyme, Apollo Tyres, Berger Paints, Castrol India, Century Enka, Claris Lifesciences, Dish TV, Future Retail, Gujarat Alkalies, Heritage Food, Hero MotoCorp, JSW Energy, Kamat Hotels, KEC International, Lupin, Monsanto, Natco Pharma, Noida Toll, PNB, Praj, Ramco, RECL, Siemens, Skipper, Tata Chemicals, Thermax, TN Petro and Wheels India.

 
KiviHealth raises $400,000 in Pre-Series A round

2017-12-07 thehindubusinessline
KiviHealth, a technology platform that aims to create next-generation medical clinic using intelligence and automation, has raised $400,000 in pre-Series A round from Chandigarh Angels Network and Claris Capital, a wholly owned subsidiary of Ahmedabad-based pharma company Claris Lifesciences.

1
Claris Life promoter seeks delisting of shares

2017-12-02 thehindubusinessline
Claris Lifesciences today said it has received a letter from the promoter Athanas Enterprise Pvt Ltd to consider delisting of shares of the pharma company from the stock exchange.

 
Torrent Pharma in advanced talks to buy Unichem’s India business for Rs3,200-3,300 crore

2017-10-30 livemint
Mumbai: Torrent Pharmaceuticals Ltd is likely in advanced discussions to acquire the domestic formulations business of Unichem Laboratories Ltd for Rs3,200-3,300 crore, two people aware of the development said on the condition of anonymity.

 
Claris Lifesciences rises 3% as RBI allows FPIs to raise stake to 49%

2017-10-18 moneycontrol
Claris Lifesciences share price gained 2.6 percent intraday Wednesday after the Reserve Bank of India has allowed foreign investors to raise their stake in the company to 49 percent.

 
RBI hikes Claris Lifesciences FPI investment limit to 49%; NRI limit at 24%

2017-10-18 indiainfoline
Foreign Institutional Investors (FIIs)/Foreign Portfolios Investors (FPIs) investment limit under Portfolio Investment Scheme in Claris Lifesciences Ltd has increased from 24%to 49% of its paid-up capital," the RBI said in a notification

 
Market Live: Sensex extends losses at open, Nifty holds 10,200; Axis Bank tanks 7%

2017-10-18 moneycontrol
10:00 am Listing: MAS Financial Services share price started off trade with a whopping premium of 44 percent on the National Stock Exchange.

 
FII Investment under PIS.

2017-10-17 indiainfoline
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.

1
Claris Lifesciences net cash stands at Rs 381 per share, stock down 7.46%

2017-10-12 moneycontrol
Drug maker Claris Lifesciences said its net cash availability stands at Rs 2077 crore translating to Rs 381 per every single share, without considering taxes.

 
Claris studying options to distribute Rs 2,077 cr to its shareholders

2017-10-12 business-standard
Ahmedabad-headquartered Claris Lifesciences that recently completed the sale of its remaining 20 per cent stake in Otsuka Pharmaceutical India Private Limited (OPIPL), the joint venture with Otsuka Pharmaceutical Factory and Mitsui & Co, to Otsuka, on Thursday said that it is considering options (dividend or share buyback) to distribute around Rs 2,077 crore to its shareholders.   In a filing to the BSE, Claris Lifesciences said that the total cash available with the company is Rs 3,614 crore.

 
Late rally lifts Sensex 348 pts; Nifty tad below 10,100; RIL up 4% ahead of Q2 nos

2017-10-12 moneycontrol
It was a spectacular rally in late trade Thursday as the Sensex surged 375 points and the Nifty reclaimed 10,100 level intraday, backed by Reliance Industries, private banks, FMCG and metals stocks. The broader markets also participated in the rally, rising for the second consecutive session.

 
Claris Lifesciences transaction raises investor concerns

2017-10-12 indiainfoline
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

23h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...